Comparison of Ga-68-DOTATATE and Ga-68-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours

Abstract

Recent studies have suggested that positron emission tomography (PET) imaging with Ga-68-labelled DOTA-somatostatin analogues (SST) like octreotide and octreotate is useful in diagnosing neuroendocrine tumours (NETs) and has superior value over both CT and planar and single photon emission computed tomography (SPECT) somatostatin receptor scintigraphy (SRS). The aim of the present study was to evaluate the role of Ga-68-DOTA-1-NaI3-octreotide (Ga-68-DOTANOC) in patients with SST receptor-expressing tumours and to compare the results of Ga-68-DOTA-D-Phe(1)-Tyr(3)-octreotate (Ga-68-DOTATATE) in the same patient population.